Founded in 1999, BIFIDO Co., Ltd. is the first listed company in the microbiome field in Korea (stock code: 2382000), which integrates strain research and development, production and sales, and provides a complete set of after-sales service solutions such as NGS analysis. Since its establishment, the company has been committed to the research and development of Bifidobacterium strains. The BIFIDO Central Research Institute and Clinical Development Headquarters have conducted in-depth cooperative research with major international research institutions and hospitals. Currently, more than 260 microbiology-related papers have been published in international journals, applied for more than 80 patents and participated in over 60 national scientific research projects. In addition, core strains such as Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI are widely used in global health food, health care products and pet food industries.